PRTA MEXC RealStocks
Own real PRTA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-18 02:17:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Prothena Corporation plc (PRTA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.25, with a market capitalization of $419.01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.70 to $11.80. This page covers its latest market performance, valuation, price trends and company information.
$419.01M | |
$7.83 | |
$8.25 | |
$7.70 | |
$7.97 | |
435.65K | |
469.09K | |
-- | |
$11.80 | |
$7.70 | |
-- | |
-- |
Prothena Corporation plc (PRTA) last closed at $8.25 as of 2026-11-18 00:31:00, up 3.51% ($0.28) from the previous close of $7.97.
During the latest regular trading session, PRTA traded between $7.70 and $8.25, with a volume of 435.65K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Prothena Corporation plc (PRTA) moved from $7.97 to $8.25, representing a gain of 3.45% ($0.27).
The stock traded between $7.70 and $8.85 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 406.56 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 13.3%
PRTA is currently trading at $8.25, placing it 13.3% of the way from its 52-week low of $7.70 to its 52-week high of $11.80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 67 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Prothena Corporation plc (PRTA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PRTA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PRTA shares and USD.
PRTA Shares to USD
1.00 PRTA shares = 8.245 USD
Calculations are estimates based on the latest available price and are for reference only.